2012
The Combination of Octreotide and Midodrine Is Not Superior to Albumin in Preventing Recurrence of Ascites After Large-Volume Paracentesis
Bari K, Miñano C, Shea M, Inayat IB, Hashem HJ, Gilles H, Heuman D, Garcia–Tsao G. The Combination of Octreotide and Midodrine Is Not Superior to Albumin in Preventing Recurrence of Ascites After Large-Volume Paracentesis. Clinical Gastroenterology And Hepatology 2012, 10: 1169-1175. PMID: 22801062, PMCID: PMC3678262, DOI: 10.1016/j.cgh.2012.06.027.Peer-Reviewed Original ResearchConceptsPostparacentesis circulatory dysfunctionRecurrence of ascitesVasoconstrictor groupAlbumin groupRefractory ascitesAscites recurrenceCombination of midodrineCombination of octreotidePlacebo-controlled trialLarge-volume paracentesisEffective blood volumeTreatment of choiceSingle intravenous doseOral midodrinePreventing RecurrenceRenal failureCirculatory dysfunctionMedian timeSerum levelsIntravenous doseIntramuscular injectionIntravenous administrationAscitesMidodrineBlood volume
2008
A Randomized, Prospective, Double-Blind, Placebo-Controlled Trial of Terlipressin for Type 1 Hepatorenal Syndrome
Sanyal AJ, Boyer T, Garcia–Tsao G, Regenstein F, Rossaro L, Appenrodt B, Blei A, Gülberg V, Sigal S, Teuber P, Group T. A Randomized, Prospective, Double-Blind, Placebo-Controlled Trial of Terlipressin for Type 1 Hepatorenal Syndrome. Gastroenterology 2008, 134: 1360-1368. PMID: 18471513, PMCID: PMC3730280, DOI: 10.1053/j.gastro.2008.02.014.Peer-Reviewed Original ResearchMeSH KeywordsDose-Response Relationship, DrugDouble-Blind MethodFemaleFollow-Up StudiesGermanyHepatorenal SyndromeHumansInjections, IntravenousKidney Function TestsLypressinMaleMiddle AgedProspective StudiesRussiaSeverity of Illness IndexShock, SepticSurvival RateTerlipressinTreatment OutcomeUnited StatesVasoconstrictor AgentsConceptsHRS type 1Type 1 HRSSCr levelsTreatment successDay 14Type 1Total adverse event rateType 1 hepatorenal syndromePlacebo-controlled clinical trialSafety of terlipressinTrial of terlipressinAdvanced liver diseaseFunctional renal failureNonfatal myocardial infarctionSerum creatinine levelsTransplantation-free survivalAdverse event ratesSyndrome type 1Arterial vasoconstrictorHepatorenal syndromeHRS reversalCreatinine levelsRenal failureRenal functionLiver disease
2001
Propranolol for the prevention of first esophageal variceal hemorrhage: A lifetime commitment?
Abraczinskas D, Ookubo R, Grace N, Groszmann R, Bosch J, Garcia‐Tsao G, Richardson C, Matloff D, Rodés J, Conn H. Propranolol for the prevention of first esophageal variceal hemorrhage: A lifetime commitment? Hepatology 2001, 34: 1096-1102. PMID: 11731997, DOI: 10.1053/jhep.2001.29305.Peer-Reviewed Original ResearchConceptsVariceal hemorrhageBeta blockersVariceal bleedingPrimary preventionFirst esophageal variceal hemorrhageWithdrawal of propranololOutcomes of patientsPlacebo-controlled trialEsophageal variceal hemorrhageGroup of patientsOriginal study populationUntreated populationBlocker therapyIndefinite administrationPlacebo groupPortal hypertensionProphylactic therapyProspective studyCumulative survivalProtective effectStudy populationHemorrhagePatientsPropranololBlockers
1999
The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis
Combes B, Markin R, Wheeler D, Rubin R, West A, Mills A, Eigenbrodt E, Maddrey W, Munoz S, Garcia‐Tsao G, Bonner G, Boyer J, Luketic V, Shiffman M, Peters M, White H, Zetterman R, Carithers R. The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis. Hepatology 1999, 30: 602-605. PMID: 10462363, PMCID: PMC3935822, DOI: 10.1002/hep.510300315.Peer-Reviewed Original ResearchConceptsFlorid duct lesionsPrimary biliary cirrhosisBile duct destructionDuct lesionsUrsodeoxycholic acidDuct destructionBiliary cirrhosisPlacebo-controlled trialNeedle biopsy specimensUDCA patientsAdvanced diseasePlacebo medicationEarly diseaseBiopsy specimensPatientsLesionsBeneficial effectsPathology literaturePrevalenceCirrhosisPlaceboMedicationsDiseaseYearsHepatopathologistBiliary bile acids in primary biliary cirrhosis: Effect of ursodeoxycholic acid
Combes B, Carithers R, Maddrey W, Munoz S, Garcia‐Tsao G, Bonner G, Boyer J, Luketic V, Shiffman M, Peters M, White H, Zetterman R, Risser R, Rossi S, Hofmann A. Biliary bile acids in primary biliary cirrhosis: Effect of ursodeoxycholic acid. Hepatology 1999, 29: 1649-1654. PMID: 10347103, PMCID: PMC4004074, DOI: 10.1002/hep.510290618.Peer-Reviewed Original ResearchMeSH KeywordsBileBile Acids and SaltsChenodeoxycholic AcidCholic AcidChromatography, GasChromatography, High Pressure LiquidDeoxycholic AcidDouble-Blind MethodDrug Administration ScheduleFemaleHumansLithocholic AcidLiver Cirrhosis, BiliaryMaleMiddle AgedPlacebosRegression AnalysisReproducibility of ResultsTime FactorsUrsodeoxycholic AcidConceptsPrimary biliary cirrhosisBile acid compositionUrsodeoxycholic acidBile acidsBiliary cirrhosisSeverity of PBCSingle bedtime dosePlacebo-controlled trialBiliary bile acidsEndogenous bile acidsMajor bile acidsBedtime dosePlacebo medicationDuodenal bileHigh-pressure liquid chromatography methodPatientsNormal personsBileSignificant decreaseCirrhosisAcid compositionCDCATaurineLiquid chromatography methodYearsLow‐dose midazolam sedation: An option for patients undergoing serial hepatic venous pressure measurements
Steinlauf A, Garcia‐Tsao G, Zakko M, Dickey K, Gupta T, Groszmann R. Low‐dose midazolam sedation: An option for patients undergoing serial hepatic venous pressure measurements. Hepatology 1999, 29: 1070-1073. PMID: 10094948, DOI: 10.1002/hep.510290421.Peer-Reviewed Original ResearchConceptsHepatic venous pressure gradientHepatic venous pressure measurementsWedged hepatic venous pressureFree hepatic venous pressureVenous pressure measurementsHepatic venous pressurePortal hypertensionVenous pressureSerial measurementsPatient comfortVenous pressure gradientDoses of midazolamDouble-blind studyDose of midazolamHigh-dose midazolamEffects of midazolamEffects of sedativesPortal pressure measurementsPressure measurementsCompensated cirrhosisVariceal hemorrhageCirrhotic patientsPharmacological therapyMidazolam sedationPrognostic index
1995
A randomized, double‐blind, placebo‐controlled trial of ursodeoxycholic acid in primary biliary cirrhosis
Combes B, Carithers R, Maddrey W, Lin D, McDonald M, Wheeler D, Eigenbrodt E, Muñoz S, Rubin R, Garcia‐Tsao G, Bonner G, West A, Boyer J, Luketic V, Shiffman M, Mills A, Peters M, White H, Zetterman R, Rossi S, Hofmann A, Markin R. A randomized, double‐blind, placebo‐controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995, 22: 759-766. PMID: 7657280, DOI: 10.1002/hep.1840220311.Peer-Reviewed Original ResearchConceptsPrimary biliary cirrhosisSerum bilirubinBiliary cirrhosisStratum 1Advanced primary biliary cirrhosisPlacebo-controlled trialBile acid poolLiver histologyPrognostic factorsTreatment failureSingle doseUrsodeoxycholic acidSevere symptomsPatientsUrsodiolLaboratory testsPlaceboHistologyBilirubinCirrhosisBiochemical testsGood responseStratum 3Acid poolLess effectOctreotide blunts postprandial splanchnic hyperemia in cirrhotic patients: A double‐blind randomized echo‐doppler study
Buonamico P, Sabbá C, Garcia‐Tsao G, Berardi E, Antonica G, Ferraioli G, Jensen J, Lerner E, Taylor K, Albano O, Groszmann R. Octreotide blunts postprandial splanchnic hyperemia in cirrhotic patients: A double‐blind randomized echo‐doppler study. Hepatology 1995, 21: 134-139. PMID: 7806146, DOI: 10.1002/hep.1840210123.Peer-Reviewed Original ResearchConceptsPortal vein cross-sectional areaPostprandial splanchnic hyperemiaSuperior mesenteric arterySMA-VCirrhotic patientsSplanchnic hyperemiaSplanchnic hemodynamicsPlacebo administrationMeal ingestionPV-VFasted stateVein cross-sectional areaEcho-Doppler studyEffect of octreotideCrossover studyMesenteric arteryPulsatility indexLiquid mealPatientsSeparate daysCross-sectional areaSignificant decreaseIngestionHyperemiaSignificant increase
1991
Propranolol in the prevention of the first hemorrhage from esophagogastric varices: A multicenter, randomized clinical trial
Conn H, Grace N, Bosch J, Groszmann R, Rodés J, Wright S, Matloff D, Garcia‐Tsao G, Fisher R, Navasa M, Drewniak S, Atterbury C, Bordas J, Lerner E, Bramante C. Propranolol in the prevention of the first hemorrhage from esophagogastric varices: A multicenter, randomized clinical trial. Hepatology 1991, 13: 902-912. PMID: 2029994, DOI: 10.1002/hep.1840130517.Peer-Reviewed Original ResearchConceptsHepatic venous pressure gradientVenous pressure gradientPlacebo groupPropranolol groupEsophageal varicesVariceal hemorrhageChild class AEffectiveness of propranololFirst variceal hemorrhageInitial variceal hemorrhageCessation of therapyPortal hypertensive gastropathyChild class BDoses of propranololLarge esophageal varicesHepatic vein cathetersBeats/minClass BPlacebo patientsPropranolol patientsAlcoholic cirrhosisHypertensive gastropathyMean followMedian doseLarge varices
1990
Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage
Groszmann R, Bosch J, Grace N, Conn H, Garcia-Tsao G, Navasa M, Alberts J, Rodes J, Fischer R, Bermann M, Rofe S, Patrick M, Lerner E. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990, 99: 1401-1407. PMID: 2210246, DOI: 10.1016/0016-5085(90)91168-6.Peer-Reviewed Original ResearchConceptsHepatic venous pressure gradientVenous pressure gradientVariceal hemorrhageEsophageal varicesHemodynamic eventsBaseline valuesHeart rateFirst variceal hemorrhagePropranolol-treated groupPropranolol-treated patientsTrial of propranololAdministration of propranololBeginning of therapyRate of survivalPortal hypertensionVariceal bleedingCirrhotic patientsPharmacological therapyVariceal sizeProtective effectMortality ratePatientsPlaceboPropranololVarices
1989
Association of transdermal nitroglycerin to vasopressin infusion in the treatment of variceal hemorrhage: A placebo‐controlled clinical trial
Bosch J, Groszmann R, García‐Pagán J, Terés J, García‐Tsao G, Navasa M, Mas A, Rodés J. Association of transdermal nitroglycerin to vasopressin infusion in the treatment of variceal hemorrhage: A placebo‐controlled clinical trial. Hepatology 1989, 10: 962-968. PMID: 2511136, DOI: 10.1002/hep.1840100612.Peer-Reviewed Original ResearchConceptsTransdermal nitroglycerinVariceal hemorrhageVariceal bleedingPlacebo-controlled clinical trialActive variceal bleedingEffectiveness of vasopressinDouble-blind techniqueSlow-release preparationHospital mortalityTransfusion requirementsRecurrent bleedingBalloon tamponadeCirrhotic patientsEmergency surgeryVasopressin infusionClinical trialsDefinitive controlDrug combinationsTotal doseNitroglycerinBleedingHemorrhagePatientsInitial controlVasopressin
1988
Colchicine in the Treatment of Cirrhosis of the Liver
Kershenobich D, Vargas F, Garcia-Tsao G, Tamayo R, Gent M, Rojkind M. Colchicine in the Treatment of Cirrhosis of the Liver. New England Journal Of Medicine 1988, 318: 1709-1713. PMID: 3287167, DOI: 10.1056/nejm198806303182602.Peer-Reviewed Original ResearchConceptsTreatment of cirrhosisPlacebo groupHistologic improvementColchicine groupSurvival rateMinimal portal fibrosisPlacebo-controlled trialPercent of patientsUse of colchicineAlcoholic cirrhosisOverall survivalPortal fibrosisMore biopsiesHepatic cirrhosisLiver biopsyPosthepatitic cirrhosisHistologic studyC. FiftyCirrhosisSide effectsPatientsCollagen synthesisLiverBiopsyPreliminary evidence
1987
Hemodynamic evaluation of isosorbide dinitrate in alcoholic cirrhosis Pharmacokinetic-hemodynamic interactions
Blei A, Garcia-Tsao G, Groszmann R, Kahrilas P, Ganger D, Morse S, Fung H. Hemodynamic evaluation of isosorbide dinitrate in alcoholic cirrhosis Pharmacokinetic-hemodynamic interactions. Gastroenterology 1987, 93: 576-583. PMID: 3301517, DOI: 10.1016/0016-5085(87)90921-8.Peer-Reviewed Original ResearchConceptsIsosorbide dinitratePortal pressureArterial pressureHemodynamic changesHemodynamic evaluationHepatic vein wedge pressureHepatic venous gradientSystemic hemodynamic changesMean arterial pressureEffects of placeboValues 4 hStable cirrhoticsAlcoholic cirrhosisCardiac indexPortal hypertensionWedge pressureHemodynamic benefitsVenous gradientVasoactive metabolitesPharmacologic agentsIndividual patientsBaseline valuesExperimental animalsDinitratePatients